Takara Bio
Kusatsu, Shiga Prefecture, Japan
Compare CAR-T CDMOs in Asia
Compare CAR-T CDMOs in Japan
Compare Lentiviral CDMOs in Asia
Compare Lentiviral CDMOs in Japan
8 confirmed programs
· 4 sponsors
· Last scored 2026-10-29
57.9
Signal Score
○ FDA Inspections
✓ Clinical Trials (8)
○ SEC Filings
✓ Press (18)
○ EMA GMP
○ MHRA GMP
Quick Facts: Takara Bio
- Signal Score
- 57.9/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Kusatsu, Shiga Prefecture, Japan
- Modalities
- CAR-T, Lentiviral
- Active Programs
- 8 confirmed from ClinicalTrials.gov across 4 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Takara Bio
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
56.2
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 4 sponsors · Modalities: CAR-T, Lentiviral · 5 programs in advanced phases (Phase 2/3)
Programs
8
Sponsors4
ModalitiesCAR-T, Lentiviral
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
NCT03155191
Study of TBI-1501 for Relapsed or Refractory Acute...
PHASE1/PHASE2
Active Not Recruiting
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 58.0/100
Sites: Shiga, JP
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals18 articles (not scored)
1 manufacturing site: Shiga, JP
Modalities: CAR-T, Lentiviral
Capacity assessment: 58.0/100
Clinical Activity 8 studies
NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in...
PHASE3
Recruiting
NCT05963217
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR)...
PHASE1
Recruiting
NCT03250325
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T...
PHASE1/PHASE2
Completed
NCT03155191
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
PHASE1/PHASE2
Active Not Recruiting
NCT02418598
AADC Gene Therapy for Parkinson's Disease
PHASE1/PHASE2
Terminated
NCT02366546
Investigator Initiated Phase 1 Study of TBI-1301
PHASE1
Unknown
NCT02134262
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced...
PHASE1/PHASE2
Unknown
NCT02096614
Investigator Initiated Phase 1 Study of TBI-1201
PHASE1
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 18 articles
Company announcements, not verified evidence. They do not change any score.
Takara Bio and SPT Labtech Automate NGS Library Prep - Technology Networks
Takara Bio and SPT Labtech Automate NGS Library Prep Technology Networks
Takara Bio USA and SPT Labtech Partner to Deliver Automated NGS Workflows - Head Topics
Takara Bio USA and SPT Labtech Partner to Deliver Automated NGS Workflows Head Topics
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies - openPR.com
AI in Plasmid DNA Manufacturing Market Is Going to Boom| Roche, Takara Bio, Agilent Technologies openPR.com
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples - Indian Pharma Post
Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples Indian Pharma Post
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research - BioSpace
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research BioSpace
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is its biotech tools leadership strong enough for steady growth AD HOC NEWS
Takara Bio and Resistomap forge deal to speed up global fight against superbugs - Indian Pharma Post
Takara Bio and Resistomap forge deal to speed up global fight against superbugs Indian Pharma Post
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies - BioSpace
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies BioSpace
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S - PharmiWeb.com
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and S PharmiWeb.com
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech gene editing strength enough to drive U.S. investor AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? - AD HOC NEWS
Takara Bio Inc stock (JP3463000004): Is biotech innovation strong enough to drive global upside? AD HOC NEWS
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - BioSpace
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation BioSpace
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep - San Jose Today - National Today
Takara Bio USA and Hamilton Partner for Automated NGS Library Prep National Today
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation - Business Wire
Takara Bio USA and Hamilton Company Partner to Automate NGS Library Preparation Business Wire
TAKARA BIO PB Ratio: 1.36 — 56% Below Median - gurufocus.com
TAKARA BIO PB Ratio: 1.36 — 56% Below Median gurufocus.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - BioSpace
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 BioSpace
Frequently Asked Questions About Takara Bio
How many clinical programs is Takara Bio linked to?
Takara Bio is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Takara Bio's CDMO Signal Score?
Takara Bio has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Takara Bio for a manufacturing program?
Use the free AI matchmaker to compare Takara Bio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
OmniaBio
Hamilton, ON
Signal Score: 61.5
AAV, Lentiviral, CAR-T, Cell Therapy
ElevateBio BaseCamp
Waltham, MA
Signal Score: 59.0
AAV, Lentiviral, CAR-T
Compare Takara Bio with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.